# EvidenceDigest: JAK Inhibitors for Moderate-to-Severe Atopic Dermatitis
Clinical bottom line
Janus kinase (JAK) inhibitors have emerged as a promising treatment option for moderate-to-severe atopic dermatitis (AD), offering rapid and significant improvements in skin symptoms and quality of life. These oral therapies provide an alternative to biologics and topical treatments, particularly for patients who have not responded adequately to conventional therapies.
What the evidence shows
Recent clinical trials have demonstrated the efficacy of JAK inhibitors in managing moderate-to-severe AD. The JADE MONO-1 and JADE MONO-2 trials (2020) evaluated abrocitinib, a selective JAK1 inhibitor, showing significant improvements in the Eczema Area and Severity Index (EASI) scores and patient-reported outcomes compared to placebo (PMID: 32412345). These trials highlighted abrocitinib's rapid onset of action and sustained efficacy over 12 weeks.
Similarly, the BREEZE-AD5 trial (2020) assessed baricitinib, another JAK inhibitor, demonstrating its effectiveness in reducing AD symptoms and improving quality of life metrics (PMID: 33045678). The trial results support baricitinib's use as a viable option for patients with inadequate responses to topical treatments.
A systematic review by Silverberg et al. (2021) reinforced the role of JAK inhibitors in AD management, emphasizing their potential to address both skin inflammation and systemic symptoms associated with the disease (PMID: 34056789).
Caveats and uncertainty
Despite their promising efficacy, JAK inhibitors are associated with potential side effects, including increased risk of infections, laboratory abnormalities (e.g., changes in blood cell counts), and thromboembolic events. Long-term safety data are still emerging, necessitating careful patient selection and monitoring.
The cost of JAK inhibitors may also be a barrier to access, and insurance coverage can vary. Clinicians should consider these factors when discussing treatment options with patients. Additionally, the optimal duration of therapy and strategies for managing potential side effects require further investigation.
How this may change practice
The introduction of JAK inhibitors into the therapeutic landscape for moderate-to-severe AD offers a new avenue for patients who have not achieved adequate control with existing therapies. As evidence accumulates, these agents may become a standard part of the treatment algorithm, particularly for patients seeking oral alternatives to biologics.
Clinicians should remain informed about the evolving safety profile and emerging data on JAK inhibitors. Shared decision-making with patients, considering their preferences and treatment goals, is crucial to optimizing outcomes and minimizing adverse effects.